Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Part of paid clinical trials in Plantation, Florida.

Sponsor: Revolution Medicines, Inc.
Study ID: NCT07777822
Phase: PHASE3
Status: Recruiting

Apply to this trial

Conditions

Lung Cancer (NSCLC)
Metastatic NSCLC - Non-Small Cell Lung Cancer
Metastatic Non-Squamous Non-Small Cell Lung Cancer
NSCLC
Non-Small Cell Lung Cancer NSCLC
Non-Squamous Non Small Cell Lung Cancer
Non-small Cell Lung Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

zoldonrasib — DRUG
oral tablets
Placebo — DRUG
oral tablets
pembrolizumab — DRUG
IV infusion or Subcutaneous injection
pemetrexed + cisplatin /carboplatin — DRUG
IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin

Study Details

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Key Dates

First listed: Aug 20, 2026
Start date: Aug 14, 2026
Status verified: Aug 2026
Primary completion: Oct 31, 2029
Completion: Feb 28, 2031

Study Design

Enrollment: 430 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Arm A: zoldonrasib + pembrolizumab + chemotherapy doublet
study drug in combination with pembrolizumab and platinum-based chemotherapy doublet
Placebo Comparator: Arm B: placebo + pembrolizumab + chemotherapy doublet
placebo in combination with pembrolizumab and platinum-based chemotherapy doublet